KR20240041354A - 8-옥소-3-아자비시클로[3.2.1]옥탄계 화합물 또는 이의 염 및 이의 제조 방법과 용도 - Google Patents
8-옥소-3-아자비시클로[3.2.1]옥탄계 화합물 또는 이의 염 및 이의 제조 방법과 용도 Download PDFInfo
- Publication number
- KR20240041354A KR20240041354A KR1020247006386A KR20247006386A KR20240041354A KR 20240041354 A KR20240041354 A KR 20240041354A KR 1020247006386 A KR1020247006386 A KR 1020247006386A KR 20247006386 A KR20247006386 A KR 20247006386A KR 20240041354 A KR20240041354 A KR 20240041354A
- Authority
- KR
- South Korea
- Prior art keywords
- alkyl
- cancer
- compound
- mmol
- azabicyclo
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/08—Bridged systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110860428.3 | 2021-07-27 | ||
| CN202110860428 | 2021-07-27 | ||
| CN202210779302.8 | 2022-07-01 | ||
| CN202210779302 | 2022-07-01 | ||
| PCT/CN2022/107932 WO2023005928A1 (zh) | 2021-07-27 | 2022-07-26 | 8-氧-3-氮杂二环[3.2.1]辛烷类化合物或其盐及其制备方法和用途 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20240041354A true KR20240041354A (ko) | 2024-03-29 |
Family
ID=85060847
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020247006386A Pending KR20240041354A (ko) | 2021-07-27 | 2022-07-26 | 8-옥소-3-아자비시클로[3.2.1]옥탄계 화합물 또는 이의 염 및 이의 제조 방법과 용도 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20240294550A1 (https=) |
| EP (1) | EP4378943A4 (https=) |
| JP (1) | JP2024527044A (https=) |
| KR (1) | KR20240041354A (https=) |
| CN (2) | CN115677730B (https=) |
| AU (1) | AU2022316931A1 (https=) |
| CA (1) | CA3227713A1 (https=) |
| IL (1) | IL310412A (https=) |
| TW (1) | TW202321256A (https=) |
| WO (1) | WO2023005928A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202602891A (zh) * | 2024-03-28 | 2026-01-16 | 大陸商勵締（杭州）醫藥科技有限公司 | 具有mTOR抑制活性的有機化合物及其用途 |
| TW202545519A (zh) * | 2024-05-15 | 2025-12-01 | 俄羅斯聯邦商拜奧卡德聯合股份公司 | 共濟失調毛細血管擴張症和Ｒａｄ３相關激酶抑制劑 |
| WO2026037494A1 (en) * | 2024-08-14 | 2026-02-19 | Eracal Therapeutics Ltd. | New compounds and their uses |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI700283B (zh) | 2014-08-04 | 2020-08-01 | 德商拜耳製藥公司 | ２-(嗎啉-４-基)-１,７-萘啶 |
| CN109071565B (zh) | 2016-05-24 | 2022-05-10 | 默克专利股份公司 | 三环杂环衍生物 |
| IL281212B2 (en) | 2018-09-07 | 2023-12-01 | Merck Patent Gmbh | 5-Morpholin-4-yl-pyrazolo[4,3-B]pyridine derivatives and their use |
| CR20210281A (es) | 2018-10-30 | 2021-10-25 | Repare Therapeutics Inc | Compuestos, composiciones farmacéuticas y métodos de preparación de compuestos y de uso como inhibidores de la cinasa atr |
| CN111848605B (zh) | 2019-04-30 | 2023-05-02 | 四川科伦博泰生物医药股份有限公司 | 一种取代吡啶并[3,4-b]吡嗪-2(1H)-酮化合物、其制备方法和用途 |
| CN112142744A (zh) * | 2019-06-28 | 2020-12-29 | 上海瑛派药业有限公司 | 取代的稠合杂芳双环化合物作为激酶抑制剂及其应用 |
| MX2022000854A (es) * | 2019-07-22 | 2022-02-10 | Repare Therapeutics Inc | Derivados de 2-morfolinopiridina sustituidos como inhibidores de la cinasa atr. |
| JP2023537055A (ja) * | 2020-08-07 | 2023-08-30 | アンテンジーン・ディスカバリー・リミテッド | Ａｔｒ阻害剤およびその使用 |
-
2022
- 2022-07-26 KR KR1020247006386A patent/KR20240041354A/ko active Pending
- 2022-07-26 IL IL310412A patent/IL310412A/en unknown
- 2022-07-26 CN CN202210884665.8A patent/CN115677730B/zh active Active
- 2022-07-26 JP JP2024504951A patent/JP2024527044A/ja active Pending
- 2022-07-26 CA CA3227713A patent/CA3227713A1/en active Pending
- 2022-07-26 TW TW111127974A patent/TW202321256A/zh unknown
- 2022-07-26 AU AU2022316931A patent/AU2022316931A1/en active Pending
- 2022-07-26 WO PCT/CN2022/107932 patent/WO2023005928A1/zh not_active Ceased
- 2022-07-26 CN CN202280052257.4A patent/CN118043325A/zh active Pending
- 2022-07-26 US US18/292,437 patent/US20240294550A1/en active Pending
- 2022-07-26 EP EP22848533.0A patent/EP4378943A4/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2024527044A (ja) | 2024-07-19 |
| WO2023005928A1 (zh) | 2023-02-02 |
| EP4378943A1 (en) | 2024-06-05 |
| TW202321256A (zh) | 2023-06-01 |
| EP4378943A4 (en) | 2024-12-11 |
| CA3227713A1 (en) | 2023-02-02 |
| AU2022316931A1 (en) | 2024-03-14 |
| CN115677730A (zh) | 2023-02-03 |
| US20240294550A1 (en) | 2024-09-05 |
| CN115677730B (zh) | 2024-11-12 |
| IL310412A (en) | 2024-03-01 |
| CN118043325A (zh) | 2024-05-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7716110B2 (ja) | ピリミジン－４（３ｈ）－オンヘテロ環式化合物、その調製方法、およびその医薬的使用 | |
| CN112300173B (zh) | 一类含氮多环类化合物、制备方法和用途 | |
| CN111217797B (zh) | Rho相关蛋白激酶抑制剂、包含其的药物组合物及其制备方法和用途 | |
| WO2024083256A1 (zh) | pan-KRAS降解剂及其制备方法和应用 | |
| WO2021218110A1 (zh) | 一类苯并噻唑基联芳基类化合物、制备方法和用途 | |
| WO2024041606A1 (zh) | 具有抗kras突变肿瘤活性的化合物 | |
| WO2020073949A1 (zh) | 含氮杂芳类衍生物调节剂、其制备方法和应用 | |
| KR20220008322A (ko) | 2환식 유도체를 포함하는 억제제, 이의 제조방법 및 용도 | |
| CN115368383A (zh) | 稠合含氮杂环类化合物、其制备方法及其在医药上的应用 | |
| WO2019000682A1 (zh) | Rho相关蛋白激酶抑制剂、包含其的药物组合物及其制备方法和用途 | |
| CN112955432B (zh) | 稠合芳香环类衍生物、其制备方法及其在医药上的应用 | |
| WO2025051242A1 (zh) | Ras抑制剂 | |
| CN117946138A (zh) | 并环含氮化合物、其中间体、制备方法和应用 | |
| KR20240041354A (ko) | 8-옥소-3-아자비시클로[3.2.1]옥탄계 화합물 또는 이의 염 및 이의 제조 방법과 용도 | |
| CN113950481A (zh) | 大环化合物 | |
| WO2022199662A1 (zh) | 一种多环化合物及其应用 | |
| CN113348170A (zh) | 联苯类衍生物抑制剂、其制备方法和应用 | |
| KR20230035036A (ko) | 이중 키나제-브로모도메인 억제제 | |
| WO2022184103A1 (zh) | 三并环化合物及其药物组合物和应用 | |
| WO2023165581A1 (zh) | 一种吡啶类衍生物及其用途 | |
| CN116375712A (zh) | 双吗啉取代的杂环化合物及其医药用途 | |
| CN114728932A (zh) | 作为egfr激酶抑制剂的多芳基化合物 | |
| CN114641476A (zh) | 一类蛋白受体激酶抑制剂的制备和应用 | |
| HK40082693A (en) | 8-oxo-3-azabicyclo[3.2.1]octane compounds or salts thereof, and preparation method and use thereof | |
| HK40082693B (zh) | 8-氧-3-氮杂二环[3.2.1]辛烷类化合物或其盐及其制备方法和用途 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
St.27 status event code: A-0-1-A10-A15-nap-PA0105 |
|
| PG1501 | Laying open of application |
St.27 status event code: A-1-1-Q10-Q12-nap-PG1501 |
|
| E13 | Pre-grant limitation requested |
Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |